PharmaCorp Rx Inc.
PCRX.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 116.50K | 77.80K | -654.00K | -310.40K | -277.60K |
| Total Depreciation and Amortization | 235.00K | 253.40K | 245.20K | 161.40K | 136.30K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -91.20K | 44.20K | 183.70K | 142.30K | -23.80K |
| Change in Net Operating Assets | 320.40K | -2.30M | 1.31M | 406.10K | 22.10K |
| Cash from Operations | 580.60K | -1.92M | 1.09M | 399.50K | -142.90K |
| Capital Expenditure | -48.60K | -61.40K | -13.90K | 1.51M | -20.60K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -236.20K | -- | 536.60K | -7.44M | -736.50K |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.40K | -12.70K | -2.23M | -- | -1.51M |
| Cash from Investing | -272.40K | -74.10K | -1.71M | -5.93M | -2.27M |
| Total Debt Issued | -- | -- | 3.16M | -- | -- |
| Total Debt Repaid | -28.70K | -106.50K | -160.80K | -61.00K | -39.50K |
| Issuance of Common Stock | -- | -- | 18.28M | 3.16M | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 225.10K | 374.50K | 450.00K | -18.20K | -- |
| Cash from Financing | 138.30K | 192.70K | 15.59M | 2.24M | -28.60K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 446.60K | -1.80M | 14.96M | -3.30M | -2.44M |